Korean J Intern Med.
2023 Jul;38(4):454-455. 10.3904/kjim.2023.248.
Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
- Affiliations
-
- 1Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea
- KMID: 2544189
- DOI: http://doi.org/10.3904/kjim.2023.248
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
- Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
- Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
- Use of sofosbuvir in chronic kidney disease: Is it necessary?
